STOCK TITAN

Qiagen N.V. (QGEN) Financials

QGEN NYSE
FY2025 annual
Revenue $2.1B +5.7% YoY
Net Income $424.9M +408.3% YoY
EPS (Diluted) $1.94 +424.3% YoY
Free Cash Flow $453.3M -10.5% YoY
Market Cap $10.2B as of Nov 20, 2026
Price / Sales 4.9x on $2.1B revenue, FY2025
Price / Earnings 24.0x on $424.9M net income, FY2025
Price / Book 2.7x on $3.8B equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QGEN SEC filings page.

Qiagen N.V. (QGEN) reported $2.1B in revenue for fiscal year 2025, up 5.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI QGEN FY2025

Qiagen's earnings rebound sharply from FY2024, but cash generation stayed broadly flat as investment rose.

FY2025 net income climbed 408.3% while operating cash flow declined 2.9% and free cash flow fell 10.5%. That gap means the reported profit recovery did not translate into more cash because capital expenditures increased 20.3%, making earnings quality less straightforward than the income statement suggests.

The margin rebound was primarily cost-led: revenue increased 5.7%, while cost of revenue fell 21.8%. Gross margin consequently recovered from 48.9% to 62.2%, and operating margin rose from 4.9% to 22.3%—a sharp reversal after FY2024's unusual compression rather than evidence of steady annual expansion.

The balance sheet became less short-term constrained but more debt-funded. Current liabilities dropped 50.9%, lifting the current ratio to 3.9x, while long-term debt nearly doubled to $1.65B; this combination indicates improved near-term coverage alongside a larger reliance on longer-term borrowing.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 66 / 100
Financial Health Score 66/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Qiagen N.V.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
72

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Qiagen N.V. scores 72/100 on it among other operating companies.

Growth
41

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Qiagen N.V. scores 41/100 on it among other operating companies.

Leverage
56

Qiagen N.V.'s net debt of $815.4M, being $1.7B of long-term debt less $839.0M of cash, came to 1.24 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Qiagen N.V. scores 56/100 among other operating companies measured the same way.

Liquidity
87

Qiagen N.V. held $3.90 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.90. Liquidity ranks operating companies on that ratio, and Qiagen N.V. scores 87/100 among other operating companies.

Cash Flow
88

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Qiagen N.V. scores 88/100 on it among other operating companies.

Returns
54

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Qiagen N.V. scores 54/100 on it among other operating companies.

Altman Z-Score Safe
3.91

Qiagen N.V. scores 3.91, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $10.2B against total liabilities of $2.5B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

Qiagen N.V. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.54x

For every $1 of reported earnings, Qiagen N.V. generates $1.54 in operating cash flow ($654.3M OCF vs $424.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
14.01x

Qiagen N.V. earns $14.01 in operating income for every $1 of interest expense ($465.9M vs $33.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$2.1B
YoY+5.7%
5Y CAGR+2.2%
10Y CAGR+5.0%

Qiagen N.V. generated $2.1B in revenue in fiscal year 2025. This represents an increase of 5.7% from the prior year.

EBITDA
$659.6M
YoY+119.2%
5Y CAGR+2.2%
10Y CAGR+5.9%

Qiagen N.V.'s EBITDA was $659.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 119.2% from the prior year.

Net Income
$424.9M
YoY+408.3%
5Y CAGR+3.4%
10Y CAGR+12.6%

Qiagen N.V. reported $424.9M in net income in fiscal year 2025. This represents an increase of 408.3% from the prior year.

EPS (Diluted)
$1.94
YoY+424.3%
5Y CAGR+4.9%
10Y CAGR+13.4%

Qiagen N.V. earned $1.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 424.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$453.3M
YoY-10.5%
5Y CAGR+6.9%
10Y CAGR+7.5%

Qiagen N.V. generated $453.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 10.5% from the prior year.

Cash & Debt
$839.0M
YoY+26.4%
5Y CAGR+7.0%
10Y CAGR+11.2%

Qiagen N.V. held $839.0M in cash against $1.7B in long-term debt as of fiscal year 2025.

Dividends Per Share
$0.25

Qiagen N.V. paid $0.25 per share in dividends in fiscal year 2025.

Shares Outstanding
217M
YoY-2.4%
5Y CAGR-1.0%
10Y CAGR-0.7%

Qiagen N.V. had 217M shares outstanding in fiscal year 2025. This represents a decrease of 2.4% from the prior year.

Margins & Returns

Gross Margin
62.2%
YoY+13.3pp
5Y change-3.7pp
10Y change-2.3pp

Qiagen N.V.'s gross margin was 62.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 13.3 percentage points from the prior year.

Operating Margin
22.3%
YoY+17.3pp
5Y change+1.6pp
10Y change+8.3pp

Qiagen N.V.'s operating margin was 22.3% in fiscal year 2025, reflecting core business profitability. This is up 17.3 percentage points from the prior year.

Net Margin
20.3%
YoY+16.1pp
5Y change+1.1pp
10Y change+10.2pp

Qiagen N.V.'s net profit margin was 20.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 16.1 percentage points from the prior year.

Return on Equity
11.3%
YoY+8.9pp
5Y change-1.6pp
10Y change+6.2pp

Qiagen N.V.'s ROE was 11.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 8.9 percentage points from the prior year.

Capital Allocation

R&D Spending
$187.5M
YoY-3.1%
5Y CAGR+4.7%
10Y CAGR+2.5%

Qiagen N.V. invested $187.5M in research and development in fiscal year 2025. This represents a decrease of 3.1% from the prior year.

Share Buybacks
$280.1M
YoY-4.1%
5Y CAGR+34.3%
10Y CAGR+29.7%

Qiagen N.V. spent $280.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 4.1% from the prior year.

Capital Expenditures
$201.0M
YoY+20.3%
5Y CAGR+8.6%
10Y CAGR+7.5%

Qiagen N.V. invested $201.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.3% from the prior year.

QGEN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QGEN annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-FFY1420-FFY1320-FFY1220-FFY1120-F
Revenue$2.1B+5.7%$2.0B+0.7%$2.0B-8.2%$2.1B-4.9%$2.3B+20.4%$1.9B+22.5%$1.5B+1.6%$1.5B+5.9%$1.4B+5.9%$1.3B+4.5%$1.3B-4.7%$1.3B+3.3%$1.3B+3.8%$1.3B+7.2%$1.2B
Cost of Revenue$790.5M-21.8%$1.0B+38.2%$731.6M-3.3%$757.0M-5.5%$800.8M+25.6%$637.6M+22.3%$521.2M+4.0%$500.9M+1.2%$495.0M+0.3%$493.3M+8.6%$454.3M-5.3%$479.6M-1.4%$486.5M+13.0%$430.4M+2.5%$419.9M
Gross Profit$1.3B+34.3%$967.4M-21.6%$1.2B-10.9%$1.4B-4.6%$1.5B+17.7%$1.2B+22.6%$1.0B+0.4%$1.0B+8.5%$922.6M+9.2%$844.7M+2.2%$826.7M-4.5%$865.2M+6.1%$815.5M-1.0%$824.0M+9.9%$749.8M
R&D Expenses$187.5M-3.1%$193.5M-2.5%$198.5M+4.6%$189.9M-0.1%$190.0M+27.4%$149.1M-5.3%$157.4M-2.7%$161.9M+5.0%$154.1M+2.8%$149.8M+2.1%$146.8M-10.3%$163.7M+12.0%$146.1M+19.3%$122.5M-6.2%$130.6M
SG&A Expenses$583.7M+3.4%$564.4M-2.6%$579.2M-4.1%$603.9M+3.3%$584.5M+11.3%$525.4M+4.2%$504.2M+1.5%$496.8M+4.0%$477.6MN/AN/AN/AN/AN/AN/A
Operating Income$465.9M+376.8%$97.7M-76.2%$409.9M-22.9%$531.5M-15.7%$630.1M+63.1%$386.4Mn/m-$26.1M-109.8%$266.6M+73.8%$153.4M+55.2%$98.8M-44.9%$179.5M+11.0%$161.7M+155.3%$63.3M-62.7%$169.8M+70.5%$99.6M
EBITDA$659.6M+119.2%$301.0M-51.1%$615.3M-16.8%$739.9M-12.4%$845.0M+42.9%$591.4M+188.1%$205.3M-56.6%$473.0M+27.9%$369.9M+18.6%$311.9M-15.9%$371.0M+2.3%$362.5M+38.0%$262.7M-28.6%$367.7M+37.7%$267.0M
Interest Expense$33.3M-24.1%$43.8M-17.9%$53.4M-8.5%$58.4M+7.1%$54.5M-23.6%$71.3M-3.9%$74.2M+10.2%$67.3M+35.4%$49.7M+27.3%$39.0M+4.3%$37.4M-4.9%$39.3M+27.4%$30.9M+31.7%$23.5M-7.5%$25.4M
Income Tax$65.4M+74.1%$37.6M-57.6%$88.5M-1.0%$89.4M-21.1%$113.2M+41.0%$80.3Mn/m-$36.3M-202.7%$35.4M-52.2%$74.0Mn/m-$23.4M-465.5%$6.4M+160.6%$2.5Mn/m-$31.8M-303.4%$15.6M+1136.4%$1.3M
Net Income$424.9M+408.3%$83.6M-75.5%$341.3M-19.4%$423.2M-17.4%$512.6M+42.7%$359.2Mn/m-$41.5M-121.8%$190.4M+371.3%$40.4M-49.8%$80.4M-38.2%$130.1M+11.8%$116.4M+68.5%$69.1M-46.7%$129.5M+34.8%$96.0M
EPS (Basic)$1.96+415.8%$0.38-74.7%$1.50-19.4%$1.86-17.3%$2.25+43.3%$1.57n/m-$0.18-121.4%$0.84+366.7%$0.18-47.1%$0.34-39.3%$0.56+12.0%$0.50+66.7%$0.30-45.5%$0.55+34.1%$0.41
EPS (Diluted)$1.94+424.3%$0.37-75.0%$1.48-19.6%$1.84-16.7%$2.21+44.4%$1.53n/m-$0.18-122.0%$0.82+382.4%$0.17-50.0%$0.34-38.2%$0.55+14.6%$0.48+65.5%$0.29-46.3%$0.54+35.0%$0.40
Diluted Shares (Avg)219M-2.6%225M-2.6%231M+0.2%230M-0.8%232M-0.9%234M+3.3%227M-2.9%233M+0.2%233M-2.5%239M+0.1%239M-1.7%243M+0.3%242M+0.6%241M+0.7%239M

QGEN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QGEN annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-FFY1420-FFY1320-FFY1220-FFY1120-F
Total Assets$6.3B+10.4%$5.7B-7.0%$6.1B-2.7%$6.3B+2.3%$6.1B+4.7%$5.9B+12.1%$5.2B-8.9%$5.7B+14.1%$5.0B+17.0%$4.3B+3.1%$4.2B-6.2%$4.5B+9.0%$4.1B0.0%$4.1B+9.6%$3.7B
Current Assets$2.0B+1.8%$2.0B-8.7%$2.1B-10.3%$2.4B+13.5%$2.1B+29.9%$1.6B+3.4%$1.6B-27.1%$2.2B+30.8%$1.6B+58.8%$1.0B+7.9%$961.4M-16.3%$1.1B+24.7%$920.9M-7.2%$992.6M+33.2%$745.4M
Cash & Equivalents$839.0M+26.4%$663.6M-0.7%$668.1M-8.6%$730.7M-17.0%$880.5M+47.2%$598.0M-4.1%$623.6M-46.2%$1.2B+76.2%$657.7M+49.8%$439.2M+51.4%$290.0M-26.1%$392.7M+18.9%$330.3M-16.2%$394.0M+78.2%$221.1M
Short-Term Investments$259.9M-46.9%$489.4M+25.6%$389.7M-43.3%$687.6M+272.1%$184.8M+57.6%$117.2M-9.5%$129.6M-44.8%$234.6M-34.7%$359.2M+286.2%$93.0M-28.9%$130.8M-28.9%$184.0M+268.6%$49.9M-44.8%$90.5M+65.7%$54.6M
Inventory$301.9M+8.1%$279.3M-29.9%$398.4M+11.3%$358.0M+9.3%$327.5M+12.5%$291.2M+70.6%$170.7M+4.8%$162.9M+4.5%$155.9M+14.2%$136.6M0.0%$136.6M+3.3%$132.3M+3.3%$128.1M-5.3%$135.3M+2.3%$132.2M
Accounts Receivable$402.6M+15.3%$349.3M-8.5%$381.9M+18.0%$323.8M-10.6%$362.1M-4.8%$380.5M-1.2%$385.1M+9.5%$351.6M+6.8%$329.1M+18.3%$278.2M+1.6%$273.9M+3.3%$265.2M+2.1%$259.7M+3.6%$250.7M+8.6%$230.8M
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0N/A$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
Goodwill$2.7B+11.3%$2.4B-2.0%$2.5B+5.2%$2.4B+0.1%$2.4B-0.6%$2.4B+10.4%$2.1B+1.5%$2.1B+4.8%$2.0B+4.5%$1.9B+2.7%$1.9B-0.6%$1.9B+1.7%$1.9B+5.4%$1.8B+1.5%$1.7B
Total Liabilities$2.5B+17.9%$2.1B-8.0%$2.3B-18.2%$2.8B-7.5%$3.1B-0.7%$3.1B+13.8%$2.7B-13.3%$3.1B+24.7%$2.5B+46.8%$1.7B+5.5%$1.6B-10.6%$1.8B+31.3%$1.4B+0.1%$1.4B+16.2%$1.2B
Current Liabilities$512.1M-50.9%$1.0B-3.5%$1.1B+10.8%$974.5M-35.8%$1.5B+165.2%$572.2M-39.9%$951.3M-2.1%$972.2M+199.3%$324.8M+5.3%$308.4M+14.9%$268.4M-37.8%$431.6M+28.1%$337.0M+26.3%$266.9M-40.9%$451.6M
Non-Current Liabilities$2.0B+84.3%$1.1B-12.0%$1.2B-33.5%$1.8B+20.5%$1.5B-38.7%$2.5B+43.0%$1.7B-18.4%$2.1B-1.5%$2.2B+56.0%$1.4B+3.7%$1.3B-1.6%$1.4B+32.8%$1.0B-6.3%$1.1B+52.2%$720.3M
Long-Term Debt$1.7B+97.0%$839.7M-8.9%$921.8M-37.4%$1.5B+34.5%$1.1B-41.8%$1.9B+32.3%$1.4B-15.0%$1.7B-5.0%$1.8B+64.8%$1.1B+1.7%$1.0B+0.8%$1.0B+23.2%$845.3M-0.1%$846.0M+89.7%$446.0M
Total Equity$3.8B+5.9%$3.6B-6.3%$3.8B+9.8%$3.5B+12.0%$3.1B+10.7%$2.8B+10.3%$2.5B-3.7%$2.6B+3.7%$2.5B-2.5%$2.6B+1.6%$2.6B-3.2%$2.6B-2.4%$2.7B0.0%$2.7B+6.5%$2.5B
Retained Earnings$2.7B+12.3%$2.4B-0.4%$2.5B+13.7%$2.2B+20.6%$1.8B+35.4%$1.3B+12.3%$1.2B-14.6%$1.4B+10.6%$1.2B-1.2%$1.3B+4.5%$1.2B+7.4%$1.1B+6.8%$1.1B+7.0%$985.4M+15.1%$855.9M

QGEN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QGEN annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-FFY1420-FFY1320-FFY1220-FFY1120-F
Operating Cash Flow$654.3M-2.9%$673.6M+46.6%$459.5M-35.8%$715.3M+11.9%$639.0M+39.6%$457.8M+38.4%$330.8M-8.0%$359.5M+25.4%$286.8M-16.0%$341.6M+7.6%$317.5M+10.3%$288.0M+11.2%$259.0M+5.7%$244.9M0.0%$244.8M
Depreciation & Amortization$193.7M-4.7%$203.3M-1.0%$205.3M-1.5%$208.4M-3.0%$214.9M+4.8%$205.0M-11.4%$231.5M+12.1%$206.4M-4.6%$216.4M+1.6%$213.1M+11.3%$191.5M-4.6%$200.8M+0.7%$199.4M+0.7%$197.9M+18.2%$167.4M
Stock-Based Compensation$50.4M+15.5%$43.6M-7.4%$47.1M-4.9%$49.5M+29.0%$38.4M-6.2%$40.9M-37.9%$65.9M+64.3%$40.1M+16.5%$34.4M+21.8%$28.3M+19.1%$23.8M-42.5%$41.3M+8.9%$37.9M+49.6%$25.4M+29.8%$19.5M
Capital Expenditures$201.0M+20.3%$167.2M+11.7%$149.7M+15.9%$129.2M-32.0%$189.9M+43.0%$132.8M+12.6%$118.0M+7.4%$109.8M+21.9%$90.1M+20.9%$74.5M-23.8%$97.8M+12.9%$86.6M+2.5%$84.5M-17.2%$102.0M+17.5%$86.8M
Free Cash Flow$453.3M-10.5%$506.4M+63.5%$309.7M-47.1%$586.0M+30.5%$449.1M+38.2%$325.0M+52.7%$212.9M-14.7%$249.7M+27.0%$196.7M-26.3%$267.1M+21.5%$219.7M+9.1%$201.4M+15.4%$174.5M+22.1%$142.9M-9.6%$158.0M
Investing Cash Flow-$305.3Mn/m-$249.2Mn/m-$87.7Mn/m-$726.8Mn/m-$202.4Mn/m-$443.3Mn/m-$222.3Mn/m-$211.4Mn/m-$464.3Mn/m-$179.1Mn/m-$146.2Mn/m-$407.6Mn/m-$251.7Mn/m-$300.9Mn/m-$540.3M
Financing Cash Flow-$179.0Mn/m-$422.9Mn/m-$433.8Mn/m-$125.8Mn/m-$150.4Mn/m-$50.1Mn/m-$639.1M-277.3%$360.4M-6.9%$387.2Mn/m-$10.6Mn/m-$258.6M-234.1%$192.8Mn/m-$68.8M-130.3%$226.6Mn/m-$310.6M
Dividends Paid$54.2Mn/m$0n/m$0N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Share Buybacks$280.1M-4.1%$292.1Mn/m$0n/m$0-100.0%$100.0M+56.2%$64.0M-14.0%$74.5M-28.9%$104.7M+71.7%$61.0Mn/m$0-100.0%$20.8M-83.6%$126.9M+47.5%$86.0M+141.3%$35.7Mn/m$0

QGEN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QGEN annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-FFY1420-FFY1320-FFY1220-FFY1120-F
Gross Margin62.2%+13.3pp48.9%-13.9pp62.8%-1.9pp64.6%+0.2pp64.4%-1.5pp65.9%+0.1pp65.9%-0.8pp66.6%+1.6pp65.1%+2.0pp63.1%-1.4pp64.5%+0.2pp64.3%+1.7pp62.6%-3.1pp65.7%+1.6pp64.1%
Operating Margin22.3%+17.3pp4.9%-15.9pp20.9%-4.0pp24.8%-3.2pp28.0%+7.3pp20.7%+22.4pp-1.7%-19.5pp17.8%+6.9pp10.8%+3.4pp7.4%-6.6pp14.0%+2.0pp12.0%+7.2pp4.9%-8.7pp13.5%+5.0pp8.5%
Net Margin20.3%+16.1pp4.2%-13.1pp17.4%-2.4pp19.8%-3.0pp22.8%+3.6pp19.2%+21.9pp-2.7%-15.4pp12.7%+9.8pp2.9%-3.2pp6.0%-4.1pp10.2%+1.5pp8.6%+3.3pp5.3%-5.0pp10.3%+2.1pp8.2%
Return on Equity11.3%+8.9pp2.3%-6.6pp9.0%-3.3pp12.2%-4.3pp16.6%+3.7pp12.8%+14.5pp-1.6%-8.9pp7.2%+5.6pp1.6%-1.5pp3.1%-2.0pp5.1%+0.7pp4.4%+1.9pp2.5%-2.2pp4.8%+1.0pp3.8%
Return on Assets6.8%+5.3pp1.5%-4.1pp5.6%-1.1pp6.7%-1.6pp8.3%+2.2pp6.1%+6.9pp-0.8%-4.1pp3.3%+2.5pp0.8%-1.1pp1.9%-1.2pp3.1%+0.5pp2.6%+0.9pp1.7%-1.5pp3.2%+0.6pp2.6%
Current Ratio3.90+2.0x1.88-0.1x1.99-0.5x2.46+1.1x1.39-1.4x2.84+1.2x1.65-0.6x2.22-2.9x5.07+1.7x3.36-0.2x3.58+0.9x2.66-0.1x2.73-1.0x3.72+2.1x1.65
Debt-to-Equity0.44+0.2x0.240.0x0.24-0.2x0.42+0.1x0.35-0.3x0.67+0.1x0.56-0.1x0.63-0.1x0.69+0.3x0.410.0x0.410.0x0.39+0.1x0.310.0x0.31+0.1x0.18
Liabilities-to-Equity0.66+0.1x0.590.0x0.61-0.2x0.81-0.2x0.99-0.1x1.100.0x1.06-0.1x1.18+0.2x0.98+0.3x0.650.0x0.63-0.1x0.68+0.2x0.510.0x0.510.0x0.46
Asset Turnover0.330.0x0.350.0x0.320.0x0.340.0x0.370.0x0.320.0x0.290.0x0.260.0x0.280.0x0.310.0x0.310.0x0.300.0x0.320.0x0.310.0x0.31
FCF Margin21.7%-3.9pp25.6%+9.8pp15.8%-11.6pp27.4%+7.4pp20.0%+2.6pp17.4%+3.4pp14.0%-2.7pp16.6%+2.7pp13.9%-6.1pp20.0%+2.8pp17.2%+2.2pp15.0%+1.6pp13.4%+2.0pp11.4%-2.1pp13.5%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Qiagen N.V. QGEN FY2025 $2.1B $424.9M 20.3% $10.2B 66/100
Icon Plc ICLR FY2025 $8.3B $229.3M 2.8% $14.0B 46/100
Revvity, Inc. RVTY FY2025 $2.9B $241.2M 8.5% $16.2B 52/100
Charles River Laboratories International, Inc. CRL FY2025 $4.0B -$144.3M -3.6% $15.1B 40/100
Guardant Health, Inc. GH FY2025 $982.0M -$416.3M -42.4% $19.7B 68/100
Medpace Holdings, Inc. MEDP FY2025 $2.5B $451.1M 17.8% $17.1B 60/100

Frequently Asked Questions

Qiagen N.V. (QGEN) reported $2.1B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Qiagen N.V. (QGEN) revenue grew by 5.7% year-over-year, from $2.0B to $2.1B in fiscal year 2025.

Yes, Qiagen N.V. (QGEN) reported a net income of $424.9M in fiscal year 2025, with a net profit margin of 20.3%.

Qiagen N.V. (QGEN) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 424.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Qiagen N.V. (QGEN) had EBITDA of $659.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Qiagen N.V. (QGEN) had $839.0M in cash and equivalents against $1.7B in long-term debt.

Qiagen N.V. (QGEN) had a gross margin of 62.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Qiagen N.V. (QGEN) had an operating margin of 22.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Qiagen N.V. (QGEN) had a net profit margin of 20.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Qiagen N.V. (QGEN) paid $0.25 per share in dividends during fiscal year 2025.

Qiagen N.V. (QGEN) has a return on equity of 11.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Qiagen N.V. (QGEN) generated $453.3M in free cash flow during fiscal year 2025. This represents a -10.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Qiagen N.V. (QGEN) generated $654.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Qiagen N.V. (QGEN) had $6.3B in total assets as of fiscal year 2025, including both current and long-term assets.

Qiagen N.V. (QGEN) invested $201.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Qiagen N.V. (QGEN) invested $187.5M in research and development during fiscal year 2025.

Yes, Qiagen N.V. (QGEN) spent $280.1M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Qiagen N.V. (QGEN) had 217M shares outstanding as of fiscal year 2025.

Qiagen N.V. (QGEN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.

Qiagen N.V. (QGEN) had a debt-to-equity ratio of 0.44 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Qiagen N.V. (QGEN) had a liabilities-to-equity ratio of 0.66 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Qiagen N.V. (QGEN) had a return on assets of 6.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Qiagen N.V. (QGEN) trades at 24.0x earnings, its market capitalization divided by $424.9M net income, FY2025. The market capitalization is $10.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Qiagen N.V. (QGEN) trades at 4.9x sales, its market capitalization divided by $2.1B revenue, FY2025. The market capitalization is $10.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Qiagen N.V. (QGEN) has an Altman Z-Score of 3.91, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Qiagen N.V. (QGEN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Qiagen N.V. (QGEN) has an earnings quality ratio of 1.54x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Qiagen N.V. (QGEN) has an interest coverage ratio of 14.01x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Qiagen N.V. (QGEN) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top